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Acute  gastrointestinal  bleeding  represents  the most  common  adverse  event  associated  with the  use  of  oral
anticoagulant  therapy.  Due  to increasing  prescription  of anticoagulants  worldwide,  gastroenterologists
are  more  and  more  called  to deal  with  bleeding  patients  taking  these  medications.  Their  management
is  challenging  because  several  issues  have  to  be  taken  into  account,  such  as  the severity  of bleeding,  the
intensity  of  anticoagulation,  the  patient’s  thrombotic  risk  and  endoscopy  ﬁndings.  The recent  introduction
into  the marketplace  of  new  direct  oral  anticoagulants,  for  whom  speciﬁc  reversal  agents  are  still  lacking,
further contributes  to make  the  decision-making  process  even  more  demanding.  Available  evidence  onral anticoagulants this topic  is  limited  and  practice  guidelines  by  gastroenterology  societies  only  marginally  address  key
issues  for  clinicians,  including  when  and how  to  reverse  coagulopathy,  the  optimal  timing  of  endoscopy
and  when  and  how  to resume  anticoagulation  thereafter.  The  present  paper  reviews  the  evidence  in
the literature  and  provides  practical  algorithms  to support  clinicians  in  the  management  of  patients  on
anticoagulants  who  present  with  acute  gastrointestinal  bleeding.
© 2015  Editrice  Gastroenterologica  Italiana  S.r.l.  Published  by Elsevier  Ltd.  All  rights  reserved.. Background
About 2% of the population in developed countries receive vita-
in  K antagonists (VKAs) (e.g., warfarin, acenocoumarol), mainly
or the prevention of thromboembolism in patients with atrial
brillation (AF) or mechanical heart valves (MHV) or for the treat-
ent of deep venous thrombosis/pulmonary embolism. These
rugs are increasingly prescribed worldwide, mostly due to the
ncreasing age of the population [1,2]. In Italy, the use of warfarin
as almost doubled during the last 10 years [3].
The burden of oral anticoagulants has also been recently broad-
ned by the introduction of new oral anticoagulants, also named
irect oral anticoagulants (DOACs), which directly inhibit either
hrombin (dabigatran, Pradaxa®, BoehringerIngelheim, Ingelheim,
ermany) or the activated coagulation factor X (rivaroxaban,
arelto®, Bayer AG, Leverkusen, Germany; apixaban, Eliquis®,
ristol-Myers Squibb, New York, NY, USA). DOACs have been
∗ Corresponding author at: Department of Gastroenterology, Valduce Hospital,
ia  Dante 11, 22100 Como, Italy. Tel.: +39 031324145; fax: +39 031308047.
E-mail address: francoradaelli@virgilio.it (F. Radaelli).
ttp://dx.doi.org/10.1016/j.dld.2015.03.029
590-8658/© 2015 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. Allapproved in Europe as alternatives to VKAs for preventing
strokes and embolic events in patients with non-valvular AF, for
thrombo-prophylaxis after major orthopaedic surgery and for the
prevention/treatment of deep venous thrombosis and pulmonary
embolism. Another direct inhibitor of the activated coagulation
factor X (edoxaban, Lixiana®, Daiichi-Sankyo, Tokyo, Japan) is cur-
rently under regulatory review in Europe [4]. These agents, which
are characterized by a predictable anticoagulant effect at ﬁxed
doses, overcome some of the VKAs pitfalls such as their narrow
therapeutic window, the need for frequent monitoring and dose
adjustments as well as the interaction with foods and/or other
drugs.
The proportion of patients with AF who take DOACs relative to
VKAs currently is 1/10–15 but this proportion will likely increase
as more and more patients shift from VKAs to DOACs [5–7].
Both VKAs and DOACs present an inherent risk of bleeding:
Warfarin users present an incidence of major haemorrhage
(including intracranial, gastrointestinal [GI], genitourinary and
respiratory sites) of 1–3% per person-year [8–13], but ﬁgures as
high as 7% per person-year have been reported in some observa-
tional studies [14–16]. The GI tract represents the most common
 rights reserved.
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bleeding site, with an age-standardized incidence rate of 5.8 per
1000 person-year [17], i.e., an approximately three-fold increased
risk as compared with the general population [18]. The propor-
tions of acute GI bleeders who take VKAs are 8–15% and 7%
for upper [19–21] and lower GI bleeding, respectively [22]. The
spectrum of endoscopic ﬁndings in VKA users who present with
non-variceal acute upper GI bleeding is similar to that observed
in patients taking no anticoagulants, with peptic ulcer being the
main cause of bleeding [23]. VKAs-related GI bleeding events are
associated with long hospitalization, relevant resource utilization,
and a 30-day mortality of up to 15% [24,25]. However, in stark
contrast to intracranial haemorrhage, warfarin exposure does not
seem to signiﬁcantly increase the GI bleeding mortality, which is
mainly affected by patient’s comorbidities [26]. A recent observa-
tional study carried out in two large community-based cohorts of
patients with AF conﬁrm that the mortality rates of patients with
a major GI haemorrhage were not signiﬁcantly different between
patients on- versus off-warfarin therapy [27].
With respect to DOACs, the risk of GI bleeding is uncertain and
reported incidences are heterogeneous. Initial evidence from AF
registration trials [28,29] and a meta-analysis [30] showed an
increased risk of bleeding as compared with warfarin at least
for dabigatran and rivaroxaban. Conversely, a more recent and
comprehensive meta-analysis of 11 phase III randomized con-
trolled trials (RCTs), found no signiﬁcant difference in the overall
incidence of major GI bleeding between DOACs and VKAs. Inter-
estingly, when trials were grouped according to the indication
for anticoagulant therapy, the risk of GI bleeding in patients
with venous thromboembolism was signiﬁcant lower with DOACs
vs. VKAs, whereas no difference was found among AF patients
[31]. Actually, postmarketing data suggest that in the real world
practice setting the observed GI bleeding risk with dabigatran in
AF patients is higher than that experienced using warfarin [32].
With respect to available data on bleeding outcomes, a small ret-
rospective study found that GI bleeders on DOACs received fewer
transfusions as compared with those on warfarin; no difference
was reported in terms of mortality and duration of hospital stay
[33].
Acute GI bleeding in patients taking anticoagulants raises
everal difﬁculties related to the balance between thrombotic
isks, associated with drug discontinuation or reversal, and hae-
orrhagic risks. Gastroenterologists who manage such patients
ave largely varying attitudes and an overall scarce knowledge
f this topic as recently reported in a national Italian survey [34].
his might be related to several factors, such as the paucity of
tudies addressing the issue of acute GI bleeding in anticoagulated
atients and the absence of RCTs comparing different management
trategies. Moreover, practice guidelines by GI professional soci-
ties only marginally address this topic as they mostly focus on
he management of anticoagulants in patients undergoing elective
rocedures [35–38]. This paucity of data is even more relevant for
OACs.
The current paper exclusively focuses on the appropriate man-
gement of VKAs and DOACs in acute GI bleeders, putting aside
anagement practices common to all GI bleeders.
. Pre-endoscopic management: anticoagulation reversal
.1. Patients on VKAs
VKA discontinuation and correction of coagulopathy is recom-
ended in VKA users who present with a clinically signiﬁcant acute
I bleeding (haematemesis, maelena, severe haematochezia caus-
ng acute aenemia) as the risks of continued bleeding are supposed
o outweigh those of thrombotic events [39–41]. The evidencer Disease 47 (2015) 621–627
documenting that an early intervention to correct VKA-related
coagulopathy improves patient outcomes is limited. In a national
audit from the UK that involved 4478 upper GI  bleeders from 212
centres, coagulopathy (deﬁned as an international normalized ratio
[INR] >1.5 and/or a prothombin time prolonged by >3 s) was the
strongest clinical predictor of failed endoscopic haemostasis [42].
Hence, it is inferred that pre-endoscopic correction of coagulopa-
thy may  be beneﬁcial for most GI bleeders on VKAs. Two  studies
showed that VKAs-related coagulopathy at presentation does not
have a negative impact on bleeding-related outcomes, provided
that anticoagulation is promptly reversed: (i) in a prospective study
by Choudari et al., 52 GI bleeders on warfarin (INR at presentation,
1.5–6.0) who received fresh frozen plasma (FFP) to decrease the
INR value to 1.5–2.5 before urgent endoscopy had rebleeding and
mortality rates similar to those observed in 50 matched controls
who did not take warfarin [43]; (ii) in a retrospective study, 128
upper GI bleeders with a supratherapeutic (≥3.0) INR on warfarin
had a signiﬁcantly lower 30-day mortality as compared with 135
matched controls who were not taking warfarin (6.3% vs. 15.5%,
respectively; p = 0.03). Almost all patients (95%) received at least
one drug to reverse anticoagulation before endoscopy, and 47% of
them normalized their INR within 24 h [25].
2.1.1. Timing of endoscopy
The optimal target INR for endoscopic therapy to be safe and
effective has yet to be determined. In the above-mentioned study
by Choudari et al. [43], endoscopic haemostasis was reported to be
as effective in warfarin users (after obtaining INR levels of 1.5–2.5)
as in controls but the number of patients with attempted endo-
scopic treatment was small (n = 23). Conversely, no data exist on
the safety and efﬁcacy of endoscopic therapy in GI bleeders with-
out previous correction of supratherapeutic INR. Considering the
recognized beneﬁts of early endoscopy in acute upper GI bleed-
ing, various authors have recommended that endoscopy should
not be postponed to correct coagulopathy in patients with a INR
≤2.5 [38]. In patients with supra-therapeutic INR values, endoscopy
should preferably be postponed until the coagulopathy is partially
or completely reversed.
2.1.2. Treatment options for VKA reversal
Treatment options for VKA reversal include administration of
vitamin K, FFP, prothrombin complex concentrate (PCC) and recom-
binant activated factor VIIa (rFVIIa) [39].
Vitamin K acts by promoting the synthesis by the liver of new
functional clotting factors II, VII, IX and X. In bleeding patients,
the intravenous (IV) route is preferred over the oral one because
it allows a more rapid correction of the INR [44]. IV vitamin K is
associated with an estimated 3/100 000 risk of anaphylaxis; thus,
a slow infusion over a minimum of 30 minutes is advised to mini-
mize this risk. Following IV infusion of 5–10 mg  vitamin K, the INR
begins to decrease within 2–4 h and usually reaches a normal range
within 24 h [39]. Lower doses may  fail to normalize the INR by 24 h,
especially in patients with more prolonged INR values, and there-
fore may  be inappropriate in bleeding patients [45,46]. Vitamin K
is not ideal for urgently reversing anticoagulation but it provides a
sustained correction of the coagulopathy, which lasts beyond that
provided by short half-lived FFP and PCC. As the response to vitamin
K may  vary among subjects and warfarin has a much longer dura-
tion of action than vitamin K, INR testing every 12 h is advised until
the INR stabilizes within normal values. A repeat dose of 5–10 mg
may  be considered whenever INR values remain elevated [46].
FFP consists of the ﬂuid portion of human blood frozen within
8 h after collection. FFP is widely available, contains vitamin K-
dependent clotting factors and has been the standard of care for
urgent reversal of warfarin coagulopathy for years in the absence
of RCTs. The recommended dose is an IV infusion of 15 mL/kg,
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orresponding to about 3–4 units of plasma (one unit = 250 mL)
n the average adult weighing 70 kg. The large infusion volume of
FP increases the duration necessary to correct coagulopathy and
uts patients at risk of ﬂuid overload. Other signiﬁcant limitations
ssociated with FFP, when urgent reversal is needed, include the
rolonged time needed to match blood group and to thaw and
ransport the units. FFP may  also be associated with transfusion-
elated acute lung injury and carries a risk, albeit minimal, of
nfection transmission as most FFP products are not virally inactiv-
ted. Time to effect of FFP is 10 min, but it takes a few hours for
artial reversal of INR and at least 9 h for complete reversal (i.e.,
NR < 1.5) [47].
PCCs are pharmacological products that contain lyophilized
nactivated concentrates of factors II, IX, and X, with variable
mounts of factor VII, derived from the cryoprecipitate supernatant
f large plasma pools after at least one viral inactivation step to
inimize the risk of pathogen transmission. Variations in factor VII
oncentrations among available PCCs have led to classify them as
ither three- or four-factor complexes (3F-PCC or 4F-PCC, respec-
ively). The factors provided by PCC products are generally not
ctivated and require activation by the clotting cascade. To pre-
ent the activation of these factors, most PCC contain heparin and
atural coagulation inhibitors (protein C, protein S). There is one
ctivated PCC (aPCC) product available (FEIBA®, factor VIII inhibitor
ypassing activity) which contains mostly activated factor VII and
ainly inactivated forms of factors II, IX and X. Two 3F-PPCs (Uman
omplex D.I®, Kedrion S.p.a, Italy and Prothromplex TIM 3®, Baxter,
ustria) and two 4F-PPCs (Conﬁdex®, CSL Behring, Germany and
ronativ®, Octapharma, Italy) are currently available in Italy and
ll are licensed for urgent reversal of VKAs. The PCCs are standard-
zed according to their factor IX content and they are administered
V, usually at the dose of 25–50 IU of factor IX/Kg, depending on
aseline INR. Main advantages of PCCs over FFP include a prompt
econstitution into a small volume (20 mL  for about 500 IU) at bed-
ide and administered regardless of the patient’s blood type with a
apid IV infusion over 20–30 min  and a faster INR correction [48,49].
n a recent RCT that included 202 VKA users with acute major bleed-
ng (52% of whom from the GI tract), 4F-PCC was  non-inferior to
FP for haemostatic efﬁcacy in the ﬁrst 24 h but it was  superior
o FFP for rapid INR lowering (62.2% vs. 9.6% of patients in the
F-PCC and FFP group, respectively, achieved an INR ≤1.3 within
0 min  of the end of infusion) [50]. In a large prospective cohort
tudy that included 822 patients with VKA-associated major bleed-
ng events, the use of PCC and of vitamin K in accordance with
stablished guidelines was associated with a signiﬁcant decrease
n seven-day mortality, particularly among patients with intracra-
ial haemorrhage, where timing of reversal strongly impacts on
utcomes [51]. A recent prospective non-randomized comparative
tudy that included 40 upper GI bleeders on warfarin with an INR
2.1 showed that patients who received 4F-PCC had almost nor-
alized their INR at 2 h (INR, 1.53), while those who  had received
FP had a INR of 2.41 at 6 h following infusion. No patient in the
CC group had active bleeding at endoscopy, compared with 7
n the FFP group (0% vs. 35%, p < 0.01). The need for endoscopic
aemostasis and the length of stay in the emergency department
ere signiﬁcantly lower in the PCC group than in the FFP group [52].
hree-factors PCC may  be less effective than 4F-PPC for warfarin
eversal, as supratherapeutic INR may  remain prolonged due to the
ersistent deﬁciency of factor VII [53,54]. Thus, where available, 4-
CCs should be preferred over 3F-PCCs for acute reversal of oral
KAs [55]. With respect to safety issues, in a retrospective cohort
tudy of 314 warfarin users, serious adverse events 7 days after
nticoagulation reversal were signiﬁcantly more frequent with FFP
s. 4F-PCC (19.5% vs. 9.7%, p = 0.014) [56]. Of note, signiﬁcantly more
atients experienced heart failure possibly related to volume over-
oad in the FFP group, whereas there was no difference in the rater Disease 47 (2015) 621–627 623
of thromboembolic events. A recent meta-analysis of 27 studies
(seven studies with 3F-PCC and 20 with 4F-PCC, 1032 patients over-
all) showed that the incidence of thromboembolic events was 0.7%
(95% conﬁdence interval [CI], 0.0–2.4) and 1.8% (95% CI, 1.0–3.0) in
patients treated with 3F-PCCs and 4F-PCCs, respectively. This sug-
gests that a low but quantiﬁable risk of thromboembolism exists in
VKA users who receive PCCs for anticoagulation reversal, this risk
being acceptable when compared with the bleeding risks [57].
Recombinant factor VIIa (rFVIIa) is a biotechnology product that
is structurally similar to the native FVIIa and enables haemostasis
by activating the extrinsic pathway. Evidence supporting the effec-
tiveness of rFVIIa for the rapid correction of prolonged INR values
and the treatment of VKA-associated bleeding is conﬁned to case
reports and small case series [58]. However, for urgent reversal of
anticoagulation the use of both rFVIIa and FEIBA has been correlated
with an unacceptably high risk of thromboembolism. None of these
agents is licensed for this indication and their routine use should
be avoided until better quality evidence supporting its effectiveness
and safety becomes available [59,60].
2.1.3. Practical management strategies
An algorithm for the management of acute GI bleeders on VKAs
is proposed (Fig. 1). In all patients, except those with minor rec-
tal bleeding and a INR <5, VKAs should be stopped and vitamin K
should be administered.
The decision to use PPCs (or FFP if unavailable) should be based
on the clinical assessment of the severity of bleeding at presen-
tation, although the INR value, the timing of endoscopy, and the
patient thrombotic risk are other relevant factors to be considered.
In critical patients who  are actively bleeding with persistent or
intermittent haemodynamic instability, coagulation factors should
be administered even in the case of therapeutic INR ranges and 4F-
PCC rather than FFP should be used [39,41]. Whenever 4F-PCC is
not available, 3F-PCC should be used. The INR should be measured
20–30 min  following the end of PCC infusion and, if it remains ≥1.5,
another dose of PCC should be administered [49]. The INR should
be measured again after 6–8 h and then daily while the situation
remains critical. IV co-administration of vitamin K is necessary to
prevent a “rebound coagulopathy”, which occurs 12–24 h after INR
normalization once the transfused factors have been cleared (the
half-life of warfarin is 20–60 h, exceeding by far those of PCC [6–8 h]
and of FFP [1.5 h–2 d]) [61].
For patients who  are not actively bleeding and who are haemo-
dynamically stable, IV administration of vitamin K alone may
represent an option in patients with therapeutic INR values. In
the case of supratherapeutic INR values, the co-administration of
PCCs or FFP could be considered whenever endoscopy is scheduled
within 6–12 h in order to allow for effective haemostasis.
In the case of minor GI bleeding (e.g., self-limited scanty
haematochezia not causing anaemia), there is no need for urgent
anticoagulation reversal; vitamin K, given orally (1–5 mg)  or IV at
low-dosage (1–2.5 mg)  may  be considered if INR values are ≥5.
2.2. Patients on DOACs
Some differences between DOACs and VKAs are important to
understand the adequate management of bleeding in DOACs users
[62]: (i) in the absence of renal or hepatic failure, the clearance
of DOACs and the subsequent loss of anticoagulation is rapid and
predictable, occurring gradually over 12–24 h; (ii) currently, no
speciﬁc reversal agent of DOACs are available for clinical use even
though the shorter half-life of DOACs compared with VKAs makes
this unavailability less critical; (iii) routine laboratory tests are not
reliable to measure the anticoagulant effect of DOACs. Although
a normal prothrombin time (PT) and a normal activated partial
thromboplastin time (aPTT) are advocated as useful tool to exclude
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Acute GI bleeding
Urgent  clinic al  ass essment  and  res uscitation, including  bloo d type  &cross-matc h for  acti ve and signific ant  blee ding
Complete blood  count / C lott ing screen (I NR, aPTT,  fibrinogen)    
Active bleeding / Shock(1) Significant bleeding without                                                        Minor rectal bleeding(3)
haemodynamic compromise(2)
1. Stop VKA
2. Acti vely re ver se anti coagulation:
- Vitamin K (5-10 mg IV infusion over 30 minutes) 
- PCC 25-50 IU/kg acc ording to baseline INR value * 
3. Check INR 20-30 minutes after PCC infusion:
1. Stop VKA
2. Acti vely re ver se anti coagulation:
-Vitamin K (5-10 mg IV infusion over 30 minutes) 
Therapeutic INR Supratherapeutic INR
No further action                
Consider urgent endoscopy
Consider PCC infusio n if
end oscopy is sc hedu led within 
6-12hours
Potential outpatient management
Consider emer gent end oscopy preferably when INR <2.5
Adequ ate correc tion (INR <1.5):
- Rechec k in 6 hours                          
Inadequ ate correction:
- Seek haematologist advice              
- Consid er PCC re-in fusion     
INR  < 5
1. Omit one VK A 
dose 
2. Close  
monit oring
5 ≤ I NR  <9
1. Stop VKA
2. Oral vitamin 
K  (1-2.5 mg) 
INR ≥ 9
1. Stop VKA
2. Vitamin K           
(2.5-5 mg oral or
1 mg IV)
- Rechec k clott ing sc ree n at 24 hours,  or sooner if cli nica l 
deteriorati on 
- Consider endoscopy evaluation as appropriate 
Fig. 1. Proposed management algorithm for acute gastrointestinal bleeders on vitamin K antagonists. aPTT, activated partial thromboplastin time; PCC, prothombin complex
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aelena, haematochezia), with shock or persistent/intermittent haemodynamic i
elf-limited haematochezia, with neither anaemia nor haemodynamic compromise
he anticoagulant effect of rivaroxaban and dabigatran, respectively
63], these coagulation assays may  be normal at trough drug levels.
ith respect to apixaban, both the PT and aPTT may  be normal in
he presence of clinically relevant on-therapy drug concentrations
64].
There are no published clinical trials or other high-quality evi-
ence addressing the management of GI bleeding on DOACs, the
linical experience is still limited and no reversal strategies have
et been fully validated; thus, most current recommendations are
ased on experts’ opinion or laboratory end-points [65–68].
.2.1. Treatment options for DOAC reversal
Watch and support – In the case of clinically signiﬁcant acute
I bleeding, DOACs should be temporary withheld. Given their
elatively short half-lives, time is the most important antidote
or DOACs, along with aggressive supportive measures, such as
uid replacement and transfusion as needed in order to preserve
aemodynamic stability and enhance renal excretion. In order to
dequately plan a watch and support strategy, it is important to
nquire about the exact time of the last DOAC intake.
Gastric lavage and oral charcoal may  be considered if DOACs have
een ingested within 2–3 h, to prevent further absorption. In an
n vitro experiment by van Ryn et al. [69], more than 99.9% of dabi-
atran was adsorbed by activated charcoal. This has not been tested
n patients and no similar study has been reported for rivaroxa-
an or apixaban. However, the use of charcoal seems reasonable,
articularly in the case of a recent dabigatran overdose.
Non speciﬁc pro-haemostatic agents,  including activated and non-
ctivated PCCs and rFVIIa may  act as reversal agents and play a
ole in the treatment of serious bleeding, but supporting evidence
s mostly limited to healthy human volunteers, animal models and
n vitro studies [70]. Recently, a few small case series provided some
vidence for these proposed reversal agents in actively bleeding
atients: bleeding was effectively controlled with activated PCC
FEIBA) and 4F-PCC, while results were less consistent with 3F-PCC mL/kg FFP only if PPC is unavailable. (1) Overt acute GI bleeding (haematemesis,
ility. (2) Overt acute GI bleeding but no haemodynamic compromise. (3) Scanty,
and rFVIIa [71]. According to recent practice guidelines [68], the
administration of either activated PCC (FEIBA) or 4F-PCC may  be
considered in a patient with life-threatening bleeding if immediate
haemostatic support is required. However, usually, 4F-PCC is pre-
ferred to FEIBA due to its lower potential prothrombotic activity
and wider prompt availability. Vice versa, there is no place for the
use of vitamin K or FFP as antidotes against DOACs; scanty data in
animal models indeed argue against their use [72].
Speciﬁc molecular antidotes for DOACs are in the early phases
of clinical trials in humans; these include a fully humanized anti-
body fragment (Fab) directly binding to dabigatran (idarucizumab,
Boehringer Ingelheim) and a truncated form of enzymatically inac-
tive factor Xa, which binds to and inhibits factor Xa inhibitors
(Andexanet alfa, Portola Pharmaceuticals, San Francisco, CA, USA)
[73]. Lastly, a small, water-soluble, cationic molecule (Arapazine,
Perosphere, Danbury, CT, USA) has been recently synthesized to
speciﬁcally bind to all DOACs, as well as unfractionated heparin and
low-molecular-weight heparin [74]. In the future, these molecules
might represent an option for the management of ongoing life-
threatening bleeding events in DOAC users.
Haemodialysis can be used to reduce the plasma concentration of
dabigatran rapidly and efﬁciently (65% at 2–4 h), and it is considered
the most effective strategy for dabigatran-associated bleeding in
patients with renal failure; however, it is not effective for other
DOACs (rivaroxaban, apixaban, and edoxaban) that are bound to
plasma proteins in higher proportions than dabigatran [75,76].
2.2.2. Practical management strategies
An algorithm for the management of acute GI bleeders on DOACs
is proposed (Fig. 2).
If the patient is haemodynamically stable and/or responds sufﬁ-ciently to resuscitation, it is advisable to simply observe the patient
closely and defer endoscopy for 12–24 h, thus allowing for drug
clearance and normal haemostatic functions to resume. The theo-
retical advantage of this approach is that endoscopic therapy may
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Acute GI bleeding
Urgent  clinic al  ass essment  and  res uscitati on, including  blood type &cross-matc h for acti ve and signific ant  blee ding
Complete b loo d count / C lott ing screen (INR, aPTT,  creati nine cle arance)   
Active bleeding / Shock(1) Significant bleeding without                                                        Minor rectal bleeding(3)
haemodynamic compromise(2)
1. Stop DOACs
2. Fluid re placement  to maintain diuresis
3.Consi der gast ric lavage (i f overdo se < 2-3 hours)  
Consi der  haemodialysis for cle ari ng dabigatran
Consider  off -label use of PCC*
1. Stop DOACs
2. Fluid replacement to maintain diuresis
Consi der end oscopy preferably after  12-24 hours
Pote ntial outpatient management
Delay or disconti nue nextdose 
Consi der  end osco py evaluation  as a ppropriat e 
Consi der  emer gent endoscopy
Fig. 2. Proposed management algorithm for acute gastrointestinal bleeders on direct oral anticoagulants (DOACs). aPTT, activated partial thromboplastin time; INR, inter-
national normalized ratio; PCC, prothombin complex concentrate; aPCC, activated prothombin complex concentrate. *Preferably 4F-PCC or aPCC, if available. (1) Overt acute
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ompromise. (3) Scanty, self-limited haematochezia, with neither anaemia nor hae
e easier and safer to perform in a patient who is not fully antico-
gulated.
Conversely, for actively bleeding patients with persistent or
ntermittent haemodynamic instability, emergent endoscopy may
e appropriate. In this case, the use of non-speciﬁc pro-haemostatic
gents to accelerate anticoagulation reversal may be considered.
ractice guidelines [68] recommend the use of such reversal agents
n patients with life-threatening bleeding but no reversal strat-
gy for DOACs has yet been validated. In a recent survey among
aematology specialists on current DOACs reversal practices, fac-
or concentrates (activated PCCs and rFVIIa) were prescribed in 41%
f dabigatran-associated bleedings [77].
Awaiting more data on the clinical effectiveness of these
trategies in bleeding patients and the availability of DOACs rever-
al agents, the current treatment approach may  depend on the
esources and experience of each centre.
. Post-endoscopic management
.1. VKAs resumption
Data from observational studies consistently favour the resump-
ion of VKAs after a major bleeding event; evidence about the timing
f VKA resumption is limited.
Three studies compared patients who resumed or did not
esume anticoagulants after GI bleeding. A retrospective cohort
tudy compared 260 patients who resumed warfarin and 182 who
id not [78]; after adjustment for potential confounders, war-
arin resumption was associated with a >10-fold lower risk of
hrombotic events (0.4% vs. 5.5%; hazard ratio [HR], 0.05; 95% CI,
.01–0.58) and a >3-fold lower risk of death (5.8% vs. 20.3%; HR,
.31; 95% CI, 0.15–0.62) while the risk of rebleeding was sim-
lar (10% vs. 5.5%; HR, 1.32; 95% CI, 0.05–3.57). A prospective
ohort study included 208 consecutive patients admitted for GI
leeding while on systemic anticoagulation (73% warfarin, 13%
OACs, 8% low-weight molecular heparin and 6% unfractionatedent haemodynamic instability. (2) Overt acute GI bleeding, but no haemodynamic
namic compromise.
heparin); 121 of these resumed anticoagulation at discharge. Over-
all, during a 90-day follow-up period, a thromboembolic event
was observed in 4% of the patients, whereas 14% of them were
readmitted for GI bleeding. At multivariate analysis, anticoagula-
tion resumption was  independently associated with a lower risk
of thromboembolism (HR, 0.121; 95% CI, 0.006–0.812), but not
with a signiﬁcantly increased risk of rebleeding (HR, 2.17; 95% CI,
0.86–6.67) or death (HR, 0.63; 95% CI, 0.21–1.89) [79]. Quereshi
et al. [80] compared 653 patients who resumed vs. 676 patients who
did not resume warfarin after GI bleeding. Resumption of anticoag-
ulation was  associated with a reduction of thromboembolic events
(HR, 0.71; 95% CI, 0.54–0.93) and no increase in rebleeding (HR,
1.18; 95% CI, 0.94–1.10). Mortality was  signiﬁcantly lower among
patients who  resumed anticoagulation (HR, 0.67; 95% CI, 0.56–0.81;
p < 0.0001).
The ideal timing to restart anticoagulation has been poorly
studied. GI practice guidelines do not speciﬁcally address this
issue and basically suggest resuming anticoagulation as soon as
the risk for cardiovascular complications is thought to outweigh
the risk for bleeding [38]. The only available data come from
the abovementioned study by Quereshi et al. [80]. In that study,
653 patients resumed warfarin at various intervals after bleeding
(<7 days [n = 62], 7–15 days [n = 51], 15–21 days [n = 58], 21–30 days
[n = 53] and >30 days [n = 429]). Mortality was lower in patients
who resumed warfarin <7 days, 7–15 days and 15–21 days vs.
>30 days following GI bleeding (p < 0.05 for all comparisons).
Patients who resumed warfarin within 7 days had an approxi-
mately two-fold higher risk of rebleeding and a non-signiﬁcant
decrease in thromboembolism as compared with patients who
resumed anticoagulation after 30 days. The incidence of rebleed-
ing was similar for all groups of patients who  resumed warfarin
>7 days following bleeding, suggesting that the second week fol-
lowing GI bleeding could be appropriate to resume VKAs in a
majority of patients. Nevertheless, the study does not provide a
stratiﬁcation of patients on the basis of their risks of bleeding or
thrombosis.
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Based on this limited evidence, VAKs should be resumed and the
deal timing lies between 7 and 30 days after the bleeding event,
ikely in the second week for most patients.
.2. DOACs resumption
Data about DOACs resumption after GI bleeding are lacking. It
an be hypothesized that the principles adopted for VKAs could
e extended to DOACs but caution is required as, unlike warfarin,
OACs induce anticoagulation within a few hours and no speciﬁc
ntidotes are currently available. The pharmokinetics of DOACs
ake the role of heparin bridge therapy unnecessary in most cases,
ut also call for prudence in DOACs resumption, which should prob-
bly be deferred after the ﬁrst week following the bleeding event.
. Areas of uncertainty
To date, there is limited information on the management of
atients with MHV  and GI bleeding. With respect to anticoagu-
ation reversal, ACC/AHA guidelines issued in 2008 raised some
oncerns on the safety of administering PCC due to potential throm-
oembolic complications, including valve thrombosis, as well as
igh-dose (5–10 mg)  IV vitamin K due to potential “warfarin resis-
ance” [81]. Low-dose (1–2.5 mg)  IV vitamin K combined with
FP was recommended in the case of major bleeding. However,
here is no evidence that bleeders with or without MHV  should be
reated differently; accordingly, the updated ACC/AHA guidelines
ecommend PCC as a reasonable alternative to FFP when urgent
eversal is required [82]. With respect to VKAs resumption, MHV
atients should be considered at high risk of thromboembolic com-
lications. In particular, prolonged anticoagulation withdrawal is a
ajor risk factor for prosthetic valve thrombosis, a serious com-
lication associated with signiﬁcant morbidity and mortality [83].
ence, it might be advisable to resume VKAs early in the sec-
nd week (ideally on day 7) considering heparin bridge therapy
ntil INR reaches the therapeutic level. For MHV  patients at high-
st thrombotic risk (mitral MHV, multiple MHVs, MHV  with prior
troke or AF, and MVH  implanted within 6 months) a potential role
or heparin bridge therapy starting 72 h after endoscopy may  be
dvocated, provided that the haemostasis is established and the
isk of rebleeding is low.
Another issue is the timing of anticoagulant resumption in
atients with clinically signiﬁcant GI haemorrhage and no source
f bleeding identiﬁed at endoscopy. In these patients, the timing
hould be decided based on estimates of the individual risks of
ebleeding and thrombosis.
Lastly, in patients for whom the endoscopist is not fully
onﬁdent in the achievement of haemostasis, no clear-cut recom-
endations on anticoagulant therapy resumption can be made. In
uch cases, a “second look” endoscopy might be indicated, although
ts role should be better evaluated.
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